Primary myocardial diffuse large B cell lymphoma. Report of one case

LUIS F. RUBALCAVA LARA1, ALEJANDRO AVILES-SALAS2, MYRNA CANDELARIA3

ABSTRACT

Primary myocardial involvement of Diffuse Large B-Cell lymphoma is extremely rare, accounting for 0.5 % of all lymphomas. We report a 65-year-old male, presenting with an acute cardiac tamponade, which was drained. A pericardial window with myocardial biopsy was carried out, disclosing a diffuse large B cell lymphoma. He received 6 cycles of rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP), without response. Finally, a palliative chemotherapy with gemcitabine plus oxaliplatin was prescribed.

Key words: Drug Therapy; Combination; Drug Therapy; Lymphoma.

Linfoma difuso de células grandes miocárdico primario. Informe de un caso

El linfoma difuso de células grandes B, primario del miocardio es muy raro. Presentamos un varón de 65 años que se presentó con un taponamiento cardíaco agudo que fue drenado. La biopsia miocárdica un mostró linfoma difuso de células grandes B, primario de miocardio. El paciente recibió 6 ciclos de quimioterapia con rituximab, ciclofosfamida, vincristina y prednisona sin respuesta. Finalmente se optó por una quimioterapia paliativa con gemcitabina y oxaliplatino.

Palabras clave: Linfoma; Quimioterapia; Terapia Combinada.

The primary cardiac lymphoma was initially characterized in 1978, when McAllister et al. assigned it as a distinct pathological categorization1. After that, two criteria were used: the strict one defines it as a non-Hodgkin lymphoma that originates and involves only in the heart or pericardium2, and the loose one, which defines it as a non-Hodgkin’s lymphoma with cardiac manifestations associated when a bulk of tumor is found in the heart3. The incidence is extremely rare and variate according to the series, they account for 1-1.3% of all cardiac tumors and 0.5% of all the extranodal lymphomas4,5. Reports of primary cardiac lymphoma are sporadic, and series usually include a few numbers of patients, in a 60-year span during the last century approximately 197 were reported6.

The most frequent histology of primary cardiac lymphomas is diffuse Large B-cell lymphoma (DLBCL), but there are also reports of Burkitt-like lymphomas7,8 and T-cell lymphoma, small lymphocytic lymphoma and plasmablastic lymphoma3. Since it is a very rare presentation, and none guidelines regarding the treatment,
we considered of interest to report a case with primary myocardial DLBCL.

Case presentation

A 65-year male patient with a prior history of pericarditis, treated during 4 months with rifampycin/ pyrazinamide/ isoniazid/ ethambutol, was transferred to a hospital because of dyspnea, anterior chest pain and leg swelling restarted along with episodes of syncope. During the clinical approach, the electrocardiogram (EKG) presented with non-sinusal rhythm, auricle-ventricle (AV) dissociation, blockade of the left His bundle and complete AV blockade. The initial echocardiogram showed a 40% ejection fraction, pericardial effusion with collapse of the right auricle. He improved after a pacemaker and pericardiocentesis. The control echocardiogram documented an increase of the ejection fraction to 60%, left ventricle with concentric hypertrophy and without hypokinesia, dilation of both auricles, mild aortic and mitral regurgitation and an infiltrative tumor which involved the anterior wall of the left ventricle. The thorax computed tomography (CT) showed a tumor infiltrating the anterior left auricle, interatrial septum, anterior wall of the left ventricle and in the adjacent pericardium. A pericardial window with myocardial biopsy, was done. The biopsy and immunohistopathological analysis diagnosed a diffuse large B cell lymphoma with CD20+, CD10+, BCL-2+, BCL-6+, MUM-1+, Ki67 70% (Figure 1). A total-body Computed Tomography-Positron Emission Tomography (CT-PET) was performed, with final report of a solid irregular tumor, with poorly defined edges, occupying the ventricular walls (predominantly the left ventricle), with extension to the pericardium, with a SUVmax of 22.6. No other hypermetabolic sites were identified. For this reason the use of immunocytochemical staining is recommended. The two procedures with an almost 100% success rate in sample biopsy are: thoracotomy (open or with mediastinoscopy), as was done in this patient, and transesophageal echocardiography-guided transjugular biopsy.

Discussion

The incidence of primary myocardial lymphoma is extremely rare and constitutes 1-1.3% of all cardiac tumors and 0.5% of all the extranodal lymphomas. The prototypical patient is a male of approximately 60 years old, as was this patient. Approximately 10% will present distant infiltration or extension to local lymph nodes. However, in this case none nodal involvement was documented. The immunocompromised state is considered a risk factor for primary extranodal DLBCL, and up to 41% are HIV positive. Interestingly, this case had none immunosuppresor comorbidity.

This patient had also an infrequent myocardial infiltration, since his major involvement was the left auricle, interatrial septum, anterior wall of the left and right ventricle and in the adjacent pericardium. A pericardial window with myocardial biopsy, was done. The biopsy and immunohistopathological analysis diagnosed a diffuse large B cell lymphoma with CD20+, CD10+, BCL-2+, BCL-6+, MUM-1+, Ki67 70% (Figure 1). A total-body Computed Tomography-Positron Emission Tomography (CT-PET) was performed, with final report of a solid irregular tumor, with poorly defined edges, occupying the ventricular walls (predominantly the left ventricle), with extension to the pericardium, with a SUVmax of 22.6. No other hypermetabolic sites were identified. The bone marrow biopsy and lumbar puncture discarded lymphoma infiltration. Serologic tests for HIV, hepatits B virus, and hepatits C virus were negative. Due to the high risk of myocardial rupture a fractioned first cycle was implanted, with 5 days of dexamethasone and in the fifth day co-infusion of vincristine (2 mg total dose). At the day +11, rituximab and cyclophosphamide were infused. We decided not to use doxorubicin, to keep the cardiac adverse events at minimum. After three cycles of R-CVP (rituximab [375 mg/m2 +1], cyclophosphamide [750 mg/m2 +1], vincristine [2 mg +1] and prednisone [100 mg, daily +1 to +5]), a partial response was documented by CT. However, at the end-of-treatment, the CT -PET demonstrated progressive disease, with an increase of the myocardial tumor with extension into the mediastinum, with a SUVmax 22. The patient refused an intensive chemotherapy treatment option and opted for palliative chemotherapy with Gemcitabine plus oxiplatin.
mode and 97% in the transesophageal. In a CT scan the bulk of the tumor usually appears hypoa-tenuated compared with healthy myocardium, its real usefulness in the initial screening of cardiac tumor is in the detection/delineation of extracardial involvement. The cardiac magnetic resonance is considered the most cost-effective image study for diagnosis and surveillance of treatment response. The usual finding is a poorly defined lesion with hypointense on T1-weighted images and isointense T2-weighted images. The use of 18-FDG-PET shows an increased tracer uptake of the cardiac mass in all cases and allows for identification of extracardiac lesions.

The low incidence of this malignancy makes it problematic to establish gold standard treatment guidelines, the most common modality was the use of anthracycline-based chemotherpy along with immunotherapy but use of surgical resection and radiotherapy have been performed. In Petrich et al. 89% of the patients received CHOP regimen, with a treatment related mortality (TRM) of 10% and an overall response (OOR) of 79%. The use of R-CEOP was used in large sized tumor without any reported adverse events, the change of doxorubicin for epirubicin was to avoid cardiotoxicity. Carras et al. has also reported other schemas, as R-miniCHOP, CEOP and “GELA Regimen”.

The fear of myocardial rupture due to chemotherapy is commonly mentioned in different publications, but the reported cases that present this complication is minimal. Nevertheless, several clinicians have tried dose modified regimens to prevent complications, especially in large sized tumors that compromise the hemodynamic system. In this case, we did a pre-phase with dexamethasone, and vincristine as has been described for aggressive tumors, also, since this patient had developed an acute tamponade, the anthracycline was suppressed to avoid major cardiovascular complications. Other authors have recommended to start with a 50% dose reduction for the first 2 cycles, after size-reduction is objectively demonstrated and myocardial rupture risk decreases the dose is then up-scaled.

The prognosis is worse compared to other subtypes of diffuse large B cell lymphoma. Petrich et al. reported that 57% of the cases died, being heart failure during the treatment the most

Figure 1. Germinal-center, Diffuse Large B-cell lymphoma. Neoplastic cells have ovoid nuclei, fine chromatine, apparent nucleoli, and poorly defined cytoplasm; HE staining, 400 x (A). The neoplastic cells were positive for CD20 (B), CD10 (C), Bcl-6 (D), BCL-2 (E), and Ki67 in 70% (F); immunohistochemical technique, 400 X.
common cause of death\(^3\). The presence of extra-cardiac extension, immunocompromise, left ventricle affection and arrhythmias are associated with poor prognosis. In particular, in this case a pacemaker was required, anthracyclines were avoided, and the first cycle was fractionated in order to avoid cardiovascular complications. The presence of left ventricular involvement and arrhythmia seem to be the most important risk factors, a median survival of 1 month was been reported for both, which is significantly lower median survival compared to those without left ventricle involvement (22 months) or arrhythmias (6 months)\(^5\). In larger series the ORR is 70\% with a CR of approximately 60\% of cases and a median OS of 12\(\text{ to } 62 \text{ months}\)\(^1\). Even in non-immunocompromised patients the CR is lower compared to non-cardiac B cell lymphoma, in Chin et al. only 61\% achieved CR\(^6\).

Of the 60\% patients that will achieve CR, approximately 50\% will relapse (the majority in the first 5 months)\(^7\). The use of second and third lines was dismal for these patients. In patients who relapsed, and a second biopsy was made a high percentage presented CMYC mutations\(^8\). A higher relapse rate has been observed in patients receiving dose adapted CHOP regimens compared to intensive regimens (ACE, ACVB, COPADM) which could give a treatment related relapse risk factor.

**Conclusion**

The primary myocardial diffuse large B cell lymphoma is a rare entity, which has been poorly reported. The lack of a standardized guideline or even expert opinion makes the treatment a challenge, so the treatment must be individualized according to the case and experience in each center.

**References**

